Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mydecine Innovations Group ( (TSE:MYCO) ) has issued an update.
Mydecine Innovations Group Inc. announced a delay in filing its annual financial statements for the fiscal year ended December 31, 2024, due to reasons previously disclosed. The audit is in progress, and updates on the timing of the filings will be provided around June 12, 2025. During the management cease trade order, the public can still trade the company’s shares, but the CEO and CFO are restricted from trading. The company remains committed to complying with regulatory requirements and will continue issuing updates as necessary.
More about Mydecine Innovations Group
Mydecine Innovations Group Inc. is a biotechnology company focused on developing innovative medications and therapies to address mental health disorders such as nicotine addiction and PTSD. The company combines advanced technology with a robust infrastructure for drug discovery and development, aiming to create breakthrough treatment solutions in areas with significant unmet needs. Mydecine collaborates with leading specialists to accelerate the development of safer and more effective psychedelic medicine.
Average Trading Volume: 69,623
Technical Sentiment Signal: Sell
Current Market Cap: C$617.6K
Learn more about MYCO stock on TipRanks’ Stock Analysis page.